Ultan McDermott,
CDF Group Leader,
The Wellcome Trust Sanger Institute
Ultan McDermott is a clinician scientist with an interest in cancer genomes and how they impact on drug response in the clinic. He is a Group Leader in the Wellcome Trust Sanger Institute as well as a practicing Oncologist at Addenbrooke's Hospital in Cambridge.
He trained as a medical oncologist and obtained a PhD in cancer biology at Queen's University, Belfast. He was accepted for a post-doctoral research position at Harvard Medical School and Massachusetts General Hospital in 2005, where he established a high-throughput cancer cell line drug screen to identify genomic alterations that could be used in the clinic to stratify patients for treatment. His research interests are in the area of predictive biomarkers to cancer therapeutics and in vitro models of drug resistance in human cancers.
Personalised Cancer Medicine in the Era of Genome Sequencing
Wednesday, 16 October 2013 at 10:45
Add to Calendar ▼2013-10-16 10:45:002013-10-16 11:45:00Europe/LondonPersonalised Cancer Medicine in the Era of Genome SequencingSELECTBIOenquiries@selectbiosciences.com
Over the last decade we have witnessed the convergence of two powerful experimental datasets towards a common goal of defining the molecular subtypes that underpin the likelihood of a cancer patient responding to treatment in the clinic. The first of these ‘experiments’ has been the systematic sequencing of large numbers of cancer genomes through the International Cancer Genome Consortium and The Cancer Genome Atlas. This endeavour is beginning to yield a complete catalogue of the cancer genes that are critical for tumourigenesis and amongst which we will find tomorrow’s biomarkers and drug targets. The second ‘experiment’ has been the use of large-scale biological models such as cancer cell lines to correlate mutations in cancer genes with drug sensitivity, such that one could begin to develop rationale clinical trials to begin to test these hypotheses. It is at this intersection of cancer genomes and biological models that there exists the opportunity to completely transform how we stratify cancer patients in the clinic for treatment.
Add to Calendar ▼2013-10-16 00:00:002013-10-17 00:00:00Europe/LondonNew Applications of NGS and PCRSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2013-10-16 10:45:002013-10-16 11:45:00Europe/LondonPersonalised Cancer Medicine in the Era of Genome SequencingSELECTBIOenquiries@selectbiosciences.com
